ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

Oncology Faces Cuts In CMS Revamp Of Physician Payments Under Part B.

July 10, 2009

DRCCA Board Gives Concept Approval To Nutrition Clinical Trials Which Could Total $52.5 Million

January 28, 1983

Antman, Clanton begin work at NCI.

December 5, 2003

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

Atrix, Sanofi In Marketing Deal For Leuprogel Products.

January 26, 2001

Federal Coordinating Council On Comparative Effectiveness Research To Hold Meeting

April 10, 2009